Details

Autor(en) / Beteiligte

• de Velasco, Guillermo
• Alonso-Gordoa, Teresa
• Rodríguez-Vida, Alejo
• Anguera, Georgia
• Campayo, Marc
• Pinto, Álvaro
• Ortega, Esther Martínez
• Gallardo, Enrique
• Núñez, Natalia Fernández
• García-Carbonero, Iciar
• Reig, Oscar
• Méndez-Vidal, María José
• Fernández-Calvo, Ovidio
• Cassinello, Natalia Vidal
• Torregrosa, Dolores
• López-Martín, Ana
• Rosero, Adriana
• Valiente, Patricia G.
• de España, Carmen Garcías
• Climent, Miguel A.
• Santasusana, Montserrat Domenech
• Sánchez, Ángel Rodríguez
• González, Isabel Chirivella
• Afonso, Ruth
• García del Muro, Xavier
• Casinello, Javier
• Fernández-Parra, Eva M.
• García Sánchez, Lourdes
• Afonso, Javier
• Polo, Susana Hernando
• Asensio, Úrsula

Titel

Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib

Ist Teil von

• Clinical genitourinary cancer, 2023-06, Vol.21 (3), p.e166-e174

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) and a complete response (CR) to the tyrosine kinase inhibitor (TKI) sunitinib are poorly known. The characteristics of these patients could reveal previously undetected associations with clinical variables. This observational, retrospective study (ATILA) used data from a registry of patients with mRCC who had received first-line sunitinib and had achieved CR from 2007 to 2018 in Spain. Sixty-two patients with CR were included; 48 patients (77.4%) received sunitinib in monotherapy and 14 (22.6%) combined with or followed by local treatment. Median age was 58.5 years (range, 32–81). Most patients (79.0%) had clear cell histology and had undergone previous nephrectomy (90.3%). The majority (70.2%) had an intermediate IMDC prognosis, 23% favorable and 7.0% poor. The median time on treatment with sunitinib was 28.2 months (IQR, 16.7–41.0) and the median time to CR was 10.9 months (IQR, 7.2–19.3). After a median follow-up of 8 years (range, 3–13 years), the median PFS was not reached. The overall median duration of complete response was 64.1 months (IQR, 32.2–99.4). The tolerance and safety profile of sunitinib was consistent with previous reports. Durable CR to sunitinib was observed in patients regardless the prognosis group, metastasis site or histology type, with 75% of patients remaining in CR after 10 years. Clinicaltrials.gov: NCT03916458. Sunitinib, a tyrosine kinase inhibitor, has been central for the treatment of metastatic renal cell carcinoma until the recent development of immunotherapy. This study analyzed the characteristics of patients with complete response to sunitinib (n=62) to understand associations with clinical variables. A complete response to sunitinib could be achieved irrespective of prognostic group, metastasis site or histology type.